Real-world evidence and AI: How EHR data is reshaping drug development decisions

AI and natural language processing now enable drug developers to mine unstructured EHR data at scale to inform trial design, patient stratification, and safety monitoring. The FDA and EMA have issued frameworks accepting real-world evidence, moving the practice from regulatory aspiration into operational use within sponsor organisations.

This Wire brief sits within Fusion42's coverage of Digital Health, Drug Discovery and AI Infrastructure.